Compounds > gw 678248
Page last updated: 2024-11-08

gw 678248

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID486532
CHEMBL ID203420
SCHEMBL ID5623473
MeSH IDM0493904

Synonyms (24)

Synonym
329939-64-2
gw8248
2-{4-chloro-2-[1-(3-chloro-5-cyano-phenyl)-methanoyl]-phenoxy}-n-(2-methyl-4-sulfamoyl-phenyl)-acetamide
gw678248
2-[4-chloro-2-(3-chloro-5-cyano-benzoyl)phenoxy]-n-(2-methyl-4-sulfamoyl-phenyl)acetamide
CHEMBL203420 ,
2-[4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy]-n-(2-methyl-4-sulfamoylphenyl)acetamide
SCHEMBL5623473
gw-8248
DTXSID00333148
bdbm50478026
2-{4-chloro-2-[(3-chloro-5-cyanophenyl)carbonyl]phenoxy}-n-(2-methyl-4-sulfamoylphenyl)acetamide
GWJ ,
Q27460949
gw-8248x
gw-678248
unii-c932c98sny
gsk678248
gw248
acetamide, n-(4-(aminosulfonyl)-2-methylphenyl)-2-(4-chloro-2-(3-chloro-5-cyanobenzoyl)phenoxy)-
c932c98sny ,
2-(4-chloro-2-(3-chloro-5-cyano-benzoyl)phenoxy)-n-(2-methyl-4-sulfamoyl-phenyl)acetamide
PD160880
AKOS040748509
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.00230.00011.076810.0000AID317948; AID331578; AID331579; AID331580; AID693596
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (62)

Assay IDTitleYearJournalArticle
AID361913Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361907Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID257916Antiviral activity against HIV1 K103N mutant using HeLa MAGI assay2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
AID331579Inhibition of HIV1 reverse transcriptase K103N mutant by SPA assay2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
AID693592Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, structure-activity relationships, and docking studies of N-phenylarylformamide derivatives (PAFAs) as non-nucleoside HIV reverse transcriptase inhibitors.
AID361915Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361911Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361909Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361919Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID693595Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, structure-activity relationships, and docking studies of N-phenylarylformamide derivatives (PAFAs) as non-nucleoside HIV reverse transcriptase inhibitors.
AID709869Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID361924Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361908Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID607810Selectivity index, ratio of CC50 for human C8166 cells to EC50 for wild type HIV1 IIIB infected in C8166 cells2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Synthesis and biological evaluation of naphthyl phenyl ethers (NPEs) as novel nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID331580Inhibition of HIV1 reverse transcriptase Y181C mutant by SPA assay2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
AID361918Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361904Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID257917Antiviral activity against HIV1 Y181C mutant using HeLa MAGI assay2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
AID607806Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Synthesis and biological evaluation of naphthyl phenyl ethers (NPEs) as novel nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID361922Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID709867Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID331582Antiviral activity against HIV1 with RT K103N mutation in human MT4 cells in presence of 10% fetal bovine serum2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
AID361916Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID612669Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis and biological evaluation of (±)-benzhydrol derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID611608Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361905Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID331583Antiviral activity against HIV1 with RT Y181C mutation in human MT4 cells in presence of 10% fetal bovine serum2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
AID693590Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, structure-activity relationships, and docking studies of N-phenylarylformamide derivatives (PAFAs) as non-nucleoside HIV reverse transcriptase inhibitors.
AID361917Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361912Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID611609Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID611664Selectivity index, ratio of CC50 for human C8166 cells to EC50 for HIV2 ROD infected in human C8166 cells2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID709868Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID611662Selectivity index, ratio of CC50 for human C8166 cells to EC50 for HIV1 3B infected in human C8166 cells2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID693594Therapeutic index, ratio of CC50 for human C8166 cells to EC50 for wild type HIV1 3B infected in human C8166 cells2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, structure-activity relationships, and docking studies of N-phenylarylformamide derivatives (PAFAs) as non-nucleoside HIV reverse transcriptase inhibitors.
AID612671Selectivity index, ratio of CC50 for human C8166 cells to EC50 for wild type HIV1 3B2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis and biological evaluation of (±)-benzhydrol derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361914Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID607809Cytotoxicity against human C8166 cells by MTT assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Synthesis and biological evaluation of naphthyl phenyl ethers (NPEs) as novel nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID361925Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID331581Antiviral activity against HIV1 in human MT4 cells in RPMI1640 media containing fetal bovine serum2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
AID361906Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID611663Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361928Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID257918Antiviral activity against HIV1 V106A mutant using HeLa MAGI assay2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
AID361926Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID693596Inhibition of wild type HIV1 reverse transcriptase activity using poly (rA)/oligo (dT)15 homopolymer template after 1 hr by ELISA2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, structure-activity relationships, and docking studies of N-phenylarylformamide derivatives (PAFAs) as non-nucleoside HIV reverse transcriptase inhibitors.
AID361910Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361927Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361920Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID611661Cytotoxicity against human C8166 cells by MTT colorimetric assay2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID607808Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Synthesis and biological evaluation of naphthyl phenyl ethers (NPEs) as novel nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID361921Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID709870Antiviral activity against HIV1 expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID331578Inhibition of HIV1 reverse transcriptase by SPA assay2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
AID612668Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis and biological evaluation of (±)-benzhydrol derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID331584Antiviral activity against HIV1 in human MT4 cells in presence of 50% normal human serum2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
AID612670Cytotoxicity against human C8166 cells by MTT assay2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Synthesis and biological evaluation of (±)-benzhydrol derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID693593Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, structure-activity relationships, and docking studies of N-phenylarylformamide derivatives (PAFAs) as non-nucleoside HIV reverse transcriptase inhibitors.
AID693591Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, structure-activity relationships, and docking studies of N-phenylarylformamide derivatives (PAFAs) as non-nucleoside HIV reverse transcriptase inhibitors.
AID607807Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction 2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Synthesis and biological evaluation of naphthyl phenyl ethers (NPEs) as novel nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID361923Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID317948Inhibition of HIV1 reverse transcriptase K103N mutant by HeLa-MAGI assay2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.27 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.4420cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		2.0410aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.9840azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		2.7430acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
etravirine
[no description available]		2.0710aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
rilpivirine
[no description available]		2.0710aminopyrimidine;
nitrile		EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
HIV Coinfection
[description not available]		02.0610
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.0610